The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | Clinical considerations when treating patients with CLL with BTK inhibitors
Paul Hampel, MD, Mayo Clinic, Rochester, MN, outlines the three currently approved covalent BTK inhibitors (BTKis) available for the treatment of patients with chronic lymphocytic leukemia (CLL), and briefly mentions some BTKi’s which are under investigation. Clinical trials have demonstrated reduced toxicity and improved efficacy when using acalabrutinib and zanubrutinib, and Dr Hampel shares his insights on applying this knowledge in a clinical setting. Dr Hampel also discusses considerations for physicians when treatment with a BTKi is terminated due to toxicity, as patients may not require immediate treatment with alternative lines of therapy. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
